Tonix Pharmaceuticals Holding financials
$9.65−2.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.8M | $0.00 | — | — | — | — | — | — |
| Gross profit | $6.5M | $2.3M | $3.0M | $0.00 | — | — | — | — | — | — |
| Gross margin | 49.3% | 23.1% | 39.0% | — | — | — | — | — | — | — |
| Operating income | -$125.7M | -$136.7M | -$118.4M | -$112.1M | -$92.3M | -$50.5M | -$28.8M | -$26.3M | -$21.3M | -$39.0M |
| Net income | -$124.0M | -$130.0M | -$116.7M | -$116.9M | -$92.3M | -$52.2M | -$31.1M | -$29.4M | -$21.1M | -$38.8M |
| Net margin | −946.2% | −1288.3% | −1501.8% | — | — | — | — | — | — | — |
| Diluted EPS | $-14.57 | $-176.60 | $-14720.25 | $-64032.00 | $-162000.00 | $-352000.00 | $-12371200.00 | $-166304000.00 | $-202816000.00 | $-986240000.00 |
| EBITDA | -$123.8M | -$74.3M | -$114.1M | -$110.8M | -$92.3M | -$50.5M | -$28.8M | -$26.3M | -$21.2M | -$38.8M |
| Operating cash flow | -$99.8M | -$60.9M | -$102.0M | -$98.1M | -$75.6M | -$48.6M | -$26.7M | -$24.0M | -$19.1M | -$37.3M |
| Free cash flow | -$103.2M | -$61.0M | -$109.9M | -$146.2M | -$110.9M | -$57.1M | -$26.7M | -$24.0M | -$19.1M | -$37.4M |
| Diluted shares | 8.5M | 0.7M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $207.6M | $98.8M | $24.9M | $120.2M | $178.7M | $77.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $7.5M | $8.9M | $0.00 | $0.00 | $0.00 |
| Total assets | $277.2M | $162.9M | $154.5M | $225.7M | $240.9M | $98.2M |
| Total liabilities | $32.0M | $23.3M | $48.9M | $18.5M | $22.2M | $10.5M |
| Shareholders' equity | $245.2M | $139.6M | $105.5M | $207.2M | $218.7M | $87.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology